Application Research Of Improved EVA In Lukang Pharmaceutical Performance Evaluation System

In recent years,people’s living standards have been continuously improved,the population has become more aging,and medical and health expenditures have increased year by year.The market size of China’s pharmaceutical industry has expanded and will maintain a high growth trend for a long period of time in the future.At the same time,pharmaceutical companies,as high-tech industries,require a large amount of R&D investment,prompting operators to reduce R&D investment for short-term operating profits.Starting from the long-term interests of enterprises,enterprises will lack core competitiveness.Therefore,it is necessary to improve the level of China’s overall pharmaceutical industry from the perspective of pharmaceutical companies themselves.In this context,the performance research of pharmaceutical companies is particularly important.This paper selects Lukang Pharmaceutical performance evaluation system,which is based on Lukang Pharmaceutical as a state-controlled listed company,which can avoid the influence of uncertain factors.However,the traditional financial performance evaluation method is still adopted within the enterprise,which is easy to adversely affect the development of the enterprise itself.The EVA that comprehensively considers the cost of liabilities and the cost of capital makes up for the shortcomings of traditional financial indicators that only consider the cost of liabilities,based on the long-term interests of enterprises.Therefore,with the help of EVA performance evaluation system,Lukang Pharmaceutical can evaluate the performance level of enterprises in an objective way,clarify the problems that arise in the process of enterprise development,and provide reference for enterprise development.At the same time,EVA can accurately determine the value of the operator’s creation value,and provide reference for investors and managers to make scientific and comprehensive investment decisions.Based on the research of EVA performance evaluation theory,this paper analyzes its shortcomings and improves it,and applies the improved EVA performance evaluation system to Lukang Pharmaceutical evaluation system.Firstly,the improved EVA performance evaluation system is divided into three parts,the selection of the first part index,the index weighting and the determination of the target value of the index.The second part uses the entropy method with objective weight to modify the subjective empowerment.The AHP method calculates a more representative index weight value;the third part builds an improved EVA performance evaluation system.Secondly,the improved EVA performance evaluation system is combined with Lukang Pharmaceutical to analyze the actual situation of enterprise performance management.Finally,combined with the actual results of Lukang Pharmaceutical performance evaluation,the corresponding safeguard measures are proposed.Through research and analysis,this paper concludes that the development trend of Lukang Pharmaceutical’s various indicators is generally the same,but there is a big gap in absolute value.Most of the indicators under the traditional financial performance evaluation system bring positive effects to enterprises,and the level of business performance is A grade.According to the improved EVA performance system,the data of each indicator is more scientific and rigorous.Most of the indicators have negative effects on the enterprise.The level of business performance is B level,which more accurately reflects the Lukang Pharmaceutical in the actual business process.